BofA/Merrill Lynch Upgrades Acadia Pharmaceuticals (ACAD) to Buy

November 8, 2016 7:08 AM EST
Get Alerts ACAD Hot Sheet
Price: $31.43 --0%

Rating Summary:
    9 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 16 | Down: 24 | New: 14
Trade ACAD Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

BofA/Merrill Lynch upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Buy with a price target of $35.00.

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $22.99 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Upgrades

Related Entities

Merrill Lynch, Bank of America

Add Your Comment